1. Home
  2. LCTX

LCTX

Lineage Cell Therapeutics Inc.

Logo Lineage Cell Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Founded: 1990 Country:
United States
United States
Employees: N/A City: CARLSBAD
Market Cap: 263.9M IPO Year: N/A
Target Price: $6.50 AVG Volume (30 days): 917.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.12 EPS Growth: N/A
52 Week Low/High: $0.84 - $1.61 Next Earning Date: 05-09-2024
Revenue: $8,945,000 Revenue Growth: -39.16%
Revenue Growth (this year): 99.33% Revenue Growth (next year): 0.06%

Share on Social Networks: